Substitutes for bear bile for the treatment of liver diseases: Research progress and future perspective

Evidence-based Complementary and Alternative Medicine

Volumn 2016, Issue , 2016, Pages

  Li, Sha ^a   Tan, Hor Yue ^a   Wang, Ning ^a   Hong, Ming ^a   Li, Lei ^a   Cheung, Fan ^a   Feng, Yibin ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEAR BILE; BILE; CHINESE MEDICINE; DRUG MECHANISM; HUMAN; LIVER DISEASE; MEDICAL RESEARCH; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRADITIONAL MEDICINE;

EID: 84964838278     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2016/4305074     Document Type: Review

References (86)

1. Y. J. Zhang, S. G. Yuan, S. B. Ruan, and Z. F. Hong, "Review on Chinese pharmacology and clinical application of bear bile, " Journal of Liaoning University of Traditional Chinese Medicine, vol. 12, no. 17, pp. 107-108, 2010.
2. Y.-H. Chen, H.-W. Xue, and C.-F. Zhou, "Research of rare animal medicine bear gall, " Chinese Journal of New Drugs, vol. 21, no. 9, pp. 952-968, 2012.
3. J. Still, "Use of animal products in traditional Chinesemedicine: environmental impact and health hazards, " Complementary Therapies in Medicine, vol. 11, no. 2, pp. 118-122, 2003.
4. Y. Feng, K. Siu, N. Wang, et al., "Bear bile: dilemma of traditional medicinal use and animal protection, " Journal of Ethnobiology and Ethnomedicine, vol. 5, no. 2, pp. 1-9, 2009.
5. C.-F. Zhou, G.-J. Gao, and Y. Liu, "Advances in studies on bear bile powder, " China Journal of Chinese Materia Medica, vol. 40, no. 7, pp. 1252-1258, 2015.
6. Z. R. Feng and J. B. Jia, "Medicinal use and substitution of bear gallbladder, " Journal of Anhui Agricultural Science, vol. 43, no. 7, pp. 150-152, 2015.
7. G. J. Kou, C. Zhang, Z. L. Wang, Q. Xu, and B. H. Wang, "Study progress on pharmacology of bear bile powder, " Chinese Journal of Drug Evaluation, vol. 31, no. 3, pp. 142-145, 2014.
8. S. Fu and J. P. Fan, "Protective effects and mechanism of bear bile powder on H2O2-induced apoptosis in PC12 cells, " China Journal of Traditional Chinese Medicine and Pharmacy, vol. 29, no. 1, pp. 55-59, 2014.
9. J. S. Park, D. H. Yoo, I. J. Lee, E. Roh, Y. Kim, and K. Han, "Therapeutic effect of whole bear bile and its components against croton oil-induced rectal inflammation in rats, " Biomolecules andTherapeutics, vol. 18, no. 1, pp. 83-91, 2010.
10. J.-Y. Zhao, W. Lin, Q.-C. Zhuang, X.-Y. Zhong, J. Peng, and Z.-F. Hong, "Bear bile powder inhibits angiogenesis in vivo and in vitro, " Chinese Journal of Integrative Medicine, vol. 21, no. 5, pp. 369-375, 2015.
11. M. Tao, W. J. Zhao, and J. W. Wang, "Research progress of pharmacology and clinical application of bear bile, " Information on Traditional ChineseMedicine, vol. 30, no. 3, pp. 153-155, 2013.
12. Y. Shi, Q. W. Zou, F. Wei, S. C. Ma, and R. C. Lin, "The research progress on bear gall powder, " Chinese Pharmaceutical Affairs, vol. 28, no. 1, pp. 82-85, 2014.
13. A. J. Dutton, C. Hepburn, and D. W. Macdonald, "A stated preference investigation into the Chinese demand for farmed vs. wild bear bile, " PLoS ONE, vol. 6, no. 7, Article ID e21243, 2011.
14. B. Yuan, Y.-L. Ren, L. Ma, H. Gu, Y. Wang, and Y.-J. Qiao, "Analysis on replacement of traditional Chinese medicine bear bile with bile acids based on drug properties, " China Journal of Chinese Materia Medica, vol. 39, no. 4, pp. 738-743, 2014.
15. N. Wang, Y. Feng, F. Cheung, et al., "A comparative study on the hepatoprotective action of bear bile and coptidis rhizoma aqueous extract on experimental liver fibrosis in rats, " BMC Complementary and Alternative Medicine, vol. 12, article 239, 2012.
16. C. M. Yang, H. Z. Wang, R. L. Hu, and Z. S. Feng, "Studies on the bile-acid compositions of several fowl and domestic animal bile, " Xinjiang Agricultural Sciences, vol. 43, no. 6, pp. 467-472, 2006.
17. M. S. Miao and X. Y. Fang, "The experimental research progress of bear bile, " Journal of Medical Forum, vol. 24, no. 11, pp. 78-79, 2003.
18. J. Gao, Y. W. Li, and X. M. Gao, "The rational application of bear bile, " Tianjin Journal of Traditional ChineseMedicine, vol. 29, no. 2, pp. 197-200, 2012.
19. N. Wang, Y. Feng, T. N. Xie, et al., "Chemical and biological analysis of active free and conjugated bile acids in animal bile using HPLC-ELSD and MTT methods, " Experimental and Therapeutic Medicine, vol. 2, no. 1, pp. 125-130, 2011.
20. X. Qiao, W. Song, X.-H. Lin, et al., "Rapid chemical analysis of bear bile: 5 minute separation and quantitation of bile acids using UHPLC-qTOF-MS, " Analytical Methods, vol. 6, no. 2, pp. 596-601, 2014.
21. D.-L. Lin, H.-C. Chang, and C.-Y. Chen, "Identification and quantitation of bile acids in bear bile by HPLC, " Journal of Food and Drug Analysis, vol. 8, no. 4, pp. 283-288, 2000.
22. Q. Luo, Q. C. Chen, Y. Wu, et al., "Chemical constituents of bear bile, " China Journal of Chinese Materia Medica, vol. 35, no. 18, pp. 2416-2419, 2010.
23. D. Bi, X.-Y. Chai, Y.-L. Song, Y. Lei, and P.-F. Tu, "Novel bile acids from bear bile powder and bile of geese, " Chemical & Pharmaceutical Bulletin, vol. 57, no. 5, pp. 528-531, 2009.
24. L.-H. Jian, X.-H. Mao, K. Wang, and S. Ji, "Structure determination of three novel bile acids from bear bile powder, " Acta Pharmaceutica Sinica, vol. 48, no. 8, pp. 1297-1300, 2013.
25. Y.-W. Li, X.-Y. Zhu, P. P.-H. But, and H.-W. Yeung, "Ethnopharmacology of bear gall bladder: I, " Journal of Ethnopharmacology, vol. 47, no. 1, pp. 27-31, 1995.
26. J. H. Boatright, J. M. Nickerson, A. G. Moring, and M. T. Pardue, "Bile acids in treatment of ocular disease, " Journal of Ocular Biology, Diseases, and Informatics, vol. 2, no. 3, pp. 149-159, 2009.
27. S. Z. Yu, "Pharmacological effects and clinical application of bear bile, " LishizhenMedicine andMateriaMedica Research, vol. 18, no. 5, pp. 707-708, 2007.
28. Y. J. Lee, "The use of bear bile as medicine versus tonic, " in Proceedings of theThird International Symposium on the Trade in Bear Parts, D. F. Williamson and M. J. Phipps, Eds., pp. 122-126, Traffic East Asia, Seoul, Republic of Korea, October 1999.
29. C. Fimognari, M. Lenzi, G. Cantelli-Forti, and P. Hrelia, "Apoptosis and modulation of cell cycle control by bile acids in human leukemia T cells, " Annals of the New York Academy of Sciences, vol. 1171, pp. 264-269, 2009.
30. X.-J. Wang, G.-L. Yan, A.-H. Zhang, et al., "Metabolomics and proteomics approaches to characterize and assess proteins of bear bile powder for hepatitis C virus, " Chinese Journal of Natural Medicines, vol. 11, no. 6, pp. 653-665, 2013.
31. J. J. Liu, X. H. Xiao, Y. Xue, and L. H. Chai, "Protective effect of bear bile powder on alcohol-induced oxidative damage in mouse primary cultured hepatocytes, " Chinese Journal of Wildlife, vol. 34, no. 4, pp. 223-225, 2013.
32. C. S. Zhou, Z. Y. Yin, W. X. Zhao, et al., "Study of bear bile on immunologic feature of hepatic stellate cells in vivo, " China Journal of Traditional Chinese Medicine and Pharmacy, vol. 26, no. 10, pp. 2251-2254, 2011.
33. C. S. Zhou, Z. Y. Yin, W. X. Zhao, et al., "Bear bile affects immunologic feature of hepatic stellate cells, " Journal of Hepatobiliary Surgery, vol. 20, no. 3, pp. 204-208, 2012.
34. Y. Liu, Z. F. Hong, W. R. Shi, et al., "Effects of compound Xiongdanyinchen granules on fat content and lipase activity in liver of hyperlipemiamodel rats, " Journal of Fujian University of Traditional Chinese Medicine, vol. 23, no. 3, pp. 21-22, 2013.
35. M.-J. Quan, R.-S. Jin, L. Piao, and D.-M. Piao, "Inhibitory effects of bear bile powder on dimethylnitrosamine-induced liver fibrosis in rats, "World Chinese Journal of Digestology, vol. 13, no. 20, pp. 2487-2490, 2005.
36. C.-S. Zhou, Z.-Y. Yin, W.-X. Zhao, et al., "Bear bile inhibits the immunosuppression activity of hepatic stellate cells in vivo, " Hepato-Gastroenterology, vol. 59, no. 117, pp. 1529-1536, 2012.
37. J.-Y. Zhao, Z.-H. Chen, W. Lin, et al., "Bear bile powder induces apoptosis of human hepatocellular carcinoma cells via mitochondrion-dependent pathway, " Chinese Journal of Integrative Medicine, vol. 20, no. 2, pp. 123-129, 2014.
38. J.-Y. Zhao, L.-Y. Liu, A.-L. Shen, et al., "Effect of bear bile powder on STAT3 pathway in hepatocellular carcinoma xenograft, " Chinese Journal of Integrated Traditional andWesternMedicine, vol. 34, no. 8, pp. 976-981, 2014.
39. J.-Y. Zhou, Z.-Y. Yin, S.-Y. Wang, et al., "Influence of bear bile on rat hepatocarcinoma induced by diethylnitrosamine, " Acta Pharmaceutica Sinica, vol. 47, no. 11, pp. 1483-1488, 2012.
40. W. Cui, S. Liu, M. Yang, et al., "Study on inhibitory effect of combined administration of bear bile powder and cyclophosphamide on colorectal cancer liver metastasis by regulating tumor microenvironment, " China Journal of Chinese Materia Medica, vol. 38, no. 7, pp. 1036-1040, 2013.
41. S. X. Yu and Y. Gao, "The pharmacological study of natural and artificial bear bile, " Jilin Chinese Medicine, vol. 25, no. 3, pp. 55-56, 2005.
42. R. Wimmer, S. Hohenester, T. Pusl, G. U. Denk, C. Rust, and U. Beuers, "Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKCα-/PKA-dependentmechanism in rat liver, " Gut, vol. 57, no. 10, pp. 1448-1454, 2008.
43. T. Pusl, T. Vennegeerts, R. Wimmer, G. U. Denk, U. Beuers, and C. Rust, "Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1, " Biochemical and Biophysical Research Communications, vol. 367, no. 1, pp. 208-212, 2008.
44. A. L. Rivard, C. J. Steer, B. T. Kren, et al., "Administration of Tauroursodeoxycholic Acid (TUDCA) reduces apoptosis following myocardial infarction in rat, " American Journal of Chinese Medicine, vol. 35, no. 2, pp. 279-295, 2007.
45. X. Qiao, M. Ye, D.-L. Pan, et al., "Differentiation of various traditional Chinese medicines derived from animal bile and gallstone: Simultaneous determination of bile acids by liquid chromatography coupled with triple quadrupole mass spectrometry, " Journal of Chromatography A, vol. 1218, no. 1, pp. 107-117, 2011.
46. C. Gluud and E. Christensen, "Ursodeoxycholic acid for primary biliary cirrhosis, " The Cochrane Database of Systematic Reviews, no. 1, Article ID CD000551, 2002.
47. D. Festi, M. Montagnani, F. Azzaroli, et al., "Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases, " Current Clinical Pharmacology, vol. 2, no. 2, pp. 155-177, 2007.
48. R. Poupon, "Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of theirmechanisms of action, " Clinics and Research in Hepatology and Gastroenterology, vol. 36, no. 1, pp. S3-S12, 2012.
49. O. F. W. James, "Ursodeoxycholic acid treatment for chronic cholestatic liver disease, " Journal of Hepatology, vol. 11, no. 1, pp. 5-8, 1990.
50. D. M. Heuman, "Hepatoprotective properties of ursodeoxycholic acid, " Gastroenterology, vol. 104, no. 6, pp. 1865-1869, 1993.
51. C. Rust and U. Beuers, "Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis, " Clinical Reviews in Allergy and Immunology, vol. 28, no. 2, pp. 135-145, 2005.
52. J. S. De Caestecker, R. P. Jazrawi, M. L. Petroni, and T. C. Northfield, "Ursodeoxycholic acid in chronic liver disease, " Gut, vol. 32, no. 9, pp. 1061-1065, 1991.
53. G. Paumgartner and U. Beuers, "Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited, " Hepatology, vol. 36, no. 3, pp. 525-531, 2002.
54. T. Pusl and U. Beuers, "Ursodeoxycholic acid treatment of vanishing bile duct syndromes, "World Journal of Gastroenterology, vol. 12, no. 22, pp. 3487-3495, 2006.
55. S. N. Cullen, C. Rust, K. Fleming, C. Edwards, U. Beuers, and R. W. Chapman, "High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective, " Journal of Hepatology, vol. 48, no. 5, pp. 792-800, 2008.
56. T. Ikegami and Y. Matsuzaki, "Ursodeoxycholic acid: mechanism of action and novel clinical applications, " Hepatology Research, vol. 38, no. 2, pp. 123-131, 2008.
57. S.-D. Wu, L. Li, and J.-Y. Wang, "Ursodeoxycholic acid for nonalcoholic steatohepatitis, " European Journal of Gastroenterology and Hepatology, vol. 24, no. 11, pp. 1247-1253, 2012.
58. V. Ratziu, V. de Ledinghen, F. Oberti, et al., "A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis, " Journal of Hepatology, vol. 54, no. 5, pp. 1011-1019, 2011.
59. A. Dechene, U. Treichel, G. Gerken, and P. Hilgard, "Effectiveness of a steroid-and ursodesoxycholic acid combination therapy with drug-induced subacute liver failure, " Hepatology, vol. 42, no. 4, supplement 1, p. 358A, 2005.
60. A. Wree, A. Dechene, K. Herzer, et al., "Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury, " Digestion, vol. 84, no. 1, pp. 54-59, 2011.
61. L. L. Liu, T. Sakaguchi, X. Cui, Y. Shirai, T. Nishimaki, and K. Hatakeyama, "Liver regeneration enhanced by orally administered ursodesoxycholic acid is mediated by immunosuppression in partially hepatectomized rats, " The American Journal of Chinese Medicine, vol. 30, no. 1, pp. 119-126, 2002.
62. S. Y. Wang, H. M. Tang, and Z. H. Peng, "A prospective, randomized, controlled clinical trial of the effects of ursodeoxycholic acid alleviating ischemia/reperfusion injury in liver transplantation, " Chinese Journal of Organ Transplantation, vol. 29, no. 3, pp. 133-136, 2008.
63. S.-C. Lim, J. E. Choi, H. S. Kang, and H. Si, "Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma, " International Journal of Cancer, vol. 126, no. 7, pp. 1582-1595, 2010.
64. R. Cao, X. D. Hu, T. Bai, et al., "Comparison of therapeutic efficacy of ursodesoxycholic acid or tauro-ursodesoxycholic acid combined with polyene phosphatidylcholine for nonalcohol fatty liver disease, " China Pharmacy, vol. 24, no. 4, pp. 365-367, 2013.
65. E.-J. Cho, J.-H. Yoon, M.-S. Kwak, et al., "Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet, " Digestive Diseases and Sciences, vol. 59, no. 7, pp. 1461-1474, 2014.
66. D. Laukens, L. Devisscher, L. Van den Bossche, et al., "Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death, " Laboratory Investigation, vol. 94, no. 12, pp. 1419-1430, 2014.
67. A. Colell, O. Coll, C. Garcia-Ruiz, et al., "Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione, " Hepatology, vol. 34, no. 5, pp. 964-971, 2001.
68. L. Falasca, G. Tisone, G. Palmieri, et al., "Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver, " Transplantation, vol. 71, no. 9, pp. 1268-1276, 2001.
69. Y.-P. Vandewyncke, D. Laukens, L. Devisscher, et al., "Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure, " Oncotarget, vol. 6, no. 29, pp. 28011-28025, 2015.
70. C. L. Zhang, C. S. Li, and X. L. Yu, "The progress of Chinese patent about ursodeoxycholic acid of bear bile active component, " China Journal of Chinese Materia Medica, vol. 37, no. 19, pp. 2851-2854, 2012.
71. S.-B. Yee, W. J. Yeo, B. S. Park, et al., "Synthetic chenodeoxycholic acid derivatives inhibit glioblastoma multiform tumor growth in vitro and in vivo, " International Journal of Oncology, vol. 27, no. 3, pp. 653-659, 2005.
72. X. C. Gu, M. D. Li, J. Q. Chang, and G. Z. Cui, "Comparison between pharmacologic actions of rabbit bile and bear bile, " China Journal of ChineseMateriaMedica, vol. 19, no. 9, pp. 556-575, 1994.
73. D. Q.-H. Wang and M. C. Carey, "Therapeutic uses of animal biles in traditional Chinese medicine: an ethnopharmacological, biophysical chemical and medicinal review, " World Journal of Gastroenterology, vol. 20, no. 29, pp. 9952-9975, 2014.
74. R. L. Chen, W. Xu, M. Sha, Z. F. Hong, and H. Li, "Advance in studies on chemical constituents of bear bile and their pharmacological effects, " Journal of Liaoning University of TCM, vol. 14, no. 7, pp. 61-64, 2012.
75. H. Y. Yan and C. C. Zou, "Determination of total cholic acid in bear bile powder, porcine gall powder, ox bile powder and chicken bile powder and study on the bacteriostatic action of these bile powder, " Chinese Journal of Hospital Pharmacy, vol. 32, no. 3, pp. 175-179, 2012.
76. S. Watanabe, T. Kamei, K. Tanaka, K. Kawasuji, T. Yoshioka, and M. Ohno, "Roles of bile acid conjugates and phospholipids in in vitro activation of pancreatic lipase by bear bile and cattle bile, " Journal of Ethnopharmacology, vol. 125, no. 2, pp. 203-206, 2009.
77. S. Watanabe and K. Tsuneyama, "Cattle bile but not bear bile or pig bile induces lipid profile changes and fatty liver injury in mice: mediation by cholic acid, " Journal of Toxicological Sciences, vol. 37, no. 1, pp. 105-121, 2012.
78. S. Pong, Y. W. Lo, and K. C. Ho, "Herbal alternatives tobear bile, " in Proceedings of theThird International Symposium on the Trade in Bear Parts: 26-28 October, 1999, Seoul, Republic of Korea, D. F. Williamson and M. J. Phipps, Eds., pp. 154-157, Traffic East Asia, 1999.
79. S. Appiah, P. Bremner, M. Heinrich, T. Kokubun, M. Simmonds, and C. Bell, "Herbal alternatives to bear bile: effects of Scutellaria baicalensis Georgi on IL-6 promoter and CYP3A4 activities, " Focus on Alternative and Complementary Therapies, vol. 11, supplement 1, p. 3, 2006.
80. F. Cheung, Y. Feng, N. Wang, M.-F. Yuen, Y. Tong, and V. T. Wong, "Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review andmeta-analysis of randomized controlled trials, " Chinese Medicine, vol. 7, no. 1, 2012.
81. Y. Feng, N. Wang, Y. Tong, and S. W. Tsao, "Berberine: an old drug but new use for liver diseases, " Planta Medica, vol. 78, no. 11, p. 1091, 2012.
82. H. Y. Tan, N. Wang, S.-W. Tsao, Z. J. Zhang, and Y. Feng, "Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in coptidis rhizome in hepatocellular carcinoma, " Integrative Cancer Therapies, vol. 13, no. 5, pp. 425-434, 2014.
83. N. Wang, Y. Feng, M. F. Zhu, et al., "Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism, " Journal of Cellular Biochemistry, vol. 111, no. 6, pp. 1426-1436, 2010.
84. N. Wang, M. Zhu, X. Wang, H.-Y. Tan, S.-W. Tsao, and Y. Feng, "Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma, " Biochimica et Biophysica Acta-Gene Regulatory Mechanisms, vol. 1839, no. 9, pp. 849-857, 2014.
85. Y. Feng, N. Wang, M. F. Zhu, Z. J. Zhang, Y. Tong, and S. W. Tsao, "Interdisciplinary approaches in study of chinese medicines: case of coptis, " International Journal ofMolecularMedicine, vol. 26, supplement 1, p. S21, 2010.
86. Y. Feng, N. Wang, X. Ye, et al., "Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats, " Journal of Ethnopharmacology, vol. 138, no. 3, pp. 683-690, 2011.